QIAGEN – Sample and Assay Technologies...Global In Vitro Diagnostics Market By Segment (2006E)...

Sample & Assay Technologies- 1 -

QIAGEN – Sample and Assay Technologies

Société Générale Corporate & Investment BankingThe European Mid & Small Caps Conference

London, November 20, 2007

Dr. Joachim Schorr Senior Vice President Global Research & Development


Safe Harbor Statement: Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, as well as the nucleic acid-based molecular diagnostics, applied testing markets and geneticvaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including fluctuations for certain events including funding, budgets, and others), difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, the management of intellectual property, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with or furnished to the U.S. Securities and Exchange Commission (SEC).

Regulation G: The following slides contain certain summary information about QIAGEN N.V.’s sales, gross profit, operating income, net income, and earnings per share for the third quarter 2007, and the comparable period of 2006, which information is presented on a “non-GAAP financial measures” basis rather than in accordance with U.S. generally accepted accounting principles (GAAP). Please review QIAGEN’s press release dated November 5, 2007, for information on the company’s operating income, net income, and earnings per share for these periods presented on a GAAP basis. Such GAAP-basis information will also be contained in the company’s reports on Form 20-F or Form 6-K to be filed with or furnished to the U.S. Securities and Exchange Commission.

Forward Looking Statements


Revenues: 2006: $ 466 million 03–06 CAGR: 15%Net income: 2006: $ 85 million 03–06 CAGR 22%1

EPS: 2006: $ 0.56 03–06 CAGR: 21%1

Product Range:>500 consumable products □Sample technologies: to collect, separate, purify, isolate,

stabilize and store samples□Assay technologies: to make such isolated target

information (DNA, RNA, proteins, etc.) visibleInstrumentation for above consumables

Customers (>400,000)Academic researchPharma/BiotechApplied Testing (veterinary, forensics, biodefense etc.)Molecular Diagnostics

IP (08/07): >1’500 patents (550+ issued, 480+ pending, 500+ licensed

Employees: >2‘600 employees based > 30 subsidiaries1 excluding acquisition, integration and relocation related charges as well as amortization of

acquired IP and equity-based compensation (SFAS 123R)

QIAGEN at a GlanceIntro


Sample & Assay Technologies

Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, DNA, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, DNA, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Talin, ...

Complexsample

DNAPureAnalyte

InformationAssayTechnologies

Target Dectected

Yes

No

SampleTechnologies

Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, DNA, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, Hemaglobins, Heptaglobins,

Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, DNA, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Talin, ...

Intro


Sample and Assay Technologies

Growth Drivers

0

20.000

40.000

60.000

80.000

100.000

120.000

140.000

160.000

180.000

200.000

220.000

240.000

260.000

280.000

1993 1994 1995 1996 1997 1998 1999 2000 2001

Financials

Intro

Technology Leadership Sales Strength

MARKETS

Research

PharmaBiomedical

MDx

Inside SalesE-commerce

Appl. Testing


Sales Strength

MARKETS

Research

PharmaBiomedical

MDx


Appl. Testing

Growth Drivers

0

20.000

40.000

60.000

80.000

100.000

120.000

140.000

160.000

180.000

200.000

220.000

240.000

260.000

280.000

1993 1994 1995 1996 1997 1998 1999 2000 2001

Financials

Sample and Assay TechnologiesTechnology Leadership

Technology Leadership


Any Analyte

QIAGEN Sample TechnologiesEnabling Access to the Content of Any Biological Sample

AnyApplicationAny

BiologicalSample



QIAGEN ConsumablesManual use or Automated on QIAGEN Instruments Technology

Leadership

20 cm

5 cm

Sample Technologies

Assay Technologies

Consumables

- Forensics- Clinical

- „Everywhere“

- Pharma

- MolecularDiagnostics

Instruments

50 cm


QIAGEN Technology and Innovation LeaderTechnology Leadership

R&D at QIAGEN:

Approx. 10% of sales

>460 employees in R&D

Germany, U.S., Switzerland and China

Chemistry, biology, physics, engineering and others

Fast, proven innovation cycles:4-5%-points of sales growth comes from new products launched in last 12 months


Growth Drivers

0

20.000

40.000

60.000

80.000

100.000

120.000

140.000

160.000

180.000

200.000

220.000

240.000

260.000

280.000

1993 1994 1995 1996 1997 1998 1999 2000 2001

Financials


QIAGEN has SignificantMarketing and Sales Power Sales Strength

Sales Strength

MARKETS

Academia

PharmaBiomedical

MDx


Appl. Testing


Strong Sales and Marketing Force

> 1,100 Sales and Marketing Professionals

Sales Strength

America Approx 52% of Sales: Sales and Marketing Force: 440

Europe Approx 41% of SalesSales and Marketing Force: 459

Asia Approx 11% of SalesSales and Marketing Force: 227

MARKETS

Biomedical

MDx


Appl. Testing

SPECIALISTS

Channels

Pharma

Research


Consumables 45% Growth CER

sample technologiesassay technologies

Instruments 39% Growth CER

Revenue DistributionThird Quarter 2007

Asia29% Growth CER

RoW2% of sales

North America70% Growth CER

Europe23% Growth CER

By Product Groups By Geographic Regions

89%

9%

52%37%

9%

Others

CER = Constant Exchange Rates

Sales Strength


Sales Strength

MARKETS

Research

PharmaBiomedical

MDx


Appl. Testing

Financials


QIAGEN is Addressing Key Growth MarketsGrowth Drivers

Growth Drivers

0

20.000

40.000

60.000

80.000

100.000

120.000

140.000

160.000

180.000

200.000

220.000

240.000

260.000

280.000

1993 1994 1995 1996 1997 1998 1999 2000 2001


Life ScienceResearch

Market Size(US$ M)

MarketGrowth

QIAGEN Revs*(% of Sales)

GrowthDriversAll figures are estimates

1,000 3-6% 27%Replacing traditionalBiomedical researchTranslational research

Pharma 1,000+ 6-10% 17%Personalized medicineClin. trials monitoringTranslational research

AppliedTesting 500 20-25% 8% Molecular biology

“going everywhere”

MolecularDiagnostics 2,800 15-20% 48%

Replacing trad. DxNew applicationsBecoming routine

Sam

ple & A

ssay Technologies

Growing By Leveraging TechnologiesGrowth Drivers

* Consolidated annualized revenues


Disseminating Technologies Into Four Markets

Product and Technology Continuum

MolecularDiagnostics Pharma Life Science

Research AppliedTesting

SAMPLETechnologies

ASSAYTechnologies

Growth Drivers


Leading in Molecular Diagnostics

Sales in MDx (run rate Q2 2007): approx. $380 million#1 (excluding blood banking and viral load monitoring)

Sample technologies: proven standard

Assay technologies: unparalleled breadth (>120 assays)PCR and real-time PCR assaysMultiplexing leader: QIAplexLeading in key assay areas (HPV)Broad platform base

Regulated portfolio – global and growing5 FDA (PMA approved or 510k cleared) products38 CE-marked assays, 6 CE-marked sample preparation products9 SFDA approved assays 98 general purpose reagents

Molecular Diagnostics

Growth Drivers


Global In Vitro Diagnostics MarketBy Segment (2006E)

MDx: Fastest Growing Segment in In-Vitro Diagnostics

Growth Drivers

Note: IVD market estimates vary by source and range between ~$29B–$35BSource: RBC Capital Markets, Nature Biotechnology (August 2006), Digene internal reports, Recap, Kalorama, BioCentury, L.E.K. Analysis

ClinicalChemistry

CAGR 2.6%Molecular

DiagnosticsUS$ 2.4B

CAGR 17.0%Blood GlucoseCAGR 11.5%

OtherCAGR 3.5%

HematologyCAGR 3.9%

Immuno-assaysCAGR 4.7%

MicrobiologyCAGR 5.7%

HemostasisCoagulation

CAGR 10.2%

Point of CareCAGR 10.9%

In Vitro Diagnostics Estimated market volume: ~US$ 33B (2006)

CAGR 2006 – 2010: 7%

Molecular Diagnostics Estimated market volume: ~US$ 2.4 billion (2006)

CAGR 2006 – 2010: 17%

Viral Infections

Non-ViralInfections

GeneticTesting

Oncology

Blood banksOthers


Significant Untapped Potential for HPV Testing

Increased global awareness of the link betweenHPV and cervical cancer

Accelerated adoption into medical guidelines

Vaccine campaigns promote awareness

New genotyping tests expand market toinclude HPV positive patients

Significant untapped potential within developingcountries

Infrastructure + breadth of combined offering key

Substantial Growth Potential - Increasing Awareness

U.S.Current tests: ~ 8.4MPenetration rate: ~ 22%

EuropeCurrent tests: ~ 2.0MPenetration rate: ~ 6%

Asia/Latin America:Current tests: 0.9MPenetration rate: ~ 3%

Asia/LatinAmerica~ $280M

U.S.~ $490M

Europe~ $350M

Total: >$1.1 billion

Growth Drivers


Multi-Channel Approach in Molecular Diagnostics

Awareness

OB/GYNstake sample

and send to lab

Laboratoryperforms test

OB/GYNscommunicate

result

Clinical Sales Force(80 Professionals)Focus: HPV Awareness

Laboratory Sales Force(170 Professionals)Focus: Complete PortfolioFocus: Transactional Sales

Direct to ConsumerAdvertising CampaignsFocus: HPV Awareness


ImplementingPre-Closing

Integration PlanIntegration Planned to Take 12 Months

Resources

AnnouncementJune 3rd

ClosingJuly 30rd

Organization Fully Implemented

Pre-Planning

0-1-2 8 96 7 10 113 42 5-3 1Line functiontakes over all

responsibilities

Analyst and R&D Days Planned in 2008

12Months

TODAY

Growth Drivers

Target CompletionJuly 2008


Integration UpdateIntegration With Clear Targets

More than 80 integration projects ongoing

Approx. 525 high level project milestones identified

o Approx. 25% of these milestones already achieved

Synergy targets

o Revenues: synergies accelerate 2009

o Costs: approx. $35-45 million in 2008

Thereof COS 10% - 15%R&D 20% - 25%S&M 20% - 25%G&A 45% - 50%

Integration Fully on Track

Sales Strength


Sales Strength

MARKETS

Research

Pharma KAMBiomedical

MDx


Appl. Testing

Growth Drivers

0

20.000

40.000

60.000

80.000

100.000

120.000

140.000

160.000

180.000

200.000

220.000

240.000

260.000

280.000

1993 1994 1995 1996 1997 1998 1999 2000 2001


QIAGEN Strong Financial Base – Exciting Model Financials

Financials


200

250

300

350

400

450

500

550

600

650

2003 2004 2005 2006 2007E

QIAGEN Revenues 2003 – 2007E

US$ millions

QIAGEN – Continuous Double Digit Revenue Growth Rates

Financials

CAGR2003-2006 = 15%

Revenues excluding the synthetic DNA business unit, sold in Q2 2004


30

40

50

60

70

80

90

100

110

2003 2004 2005 2006 2007E

QIAGEN Net Income 2003 – 2007E

US$ millions

QIAGEN – Strong Earnings Engine

US$ 0.32 US$ 0.56EPSAdj.

US$ 0.61-US$ 0.62

US$ 0.46US$ 0.39

All figures excluding acquisition, integration and relocation related charges as well asamortization of acquired IP and equity-based compensation (SFAS 123R)

Financials

CAGR2003-2006 = 22%


43%30.643.7Operating income (US$m), adj.2

42%21.931.1Net income (US$m), adj.3

21%0.140.17EPS (US$), adj.3

26%25%Operating margin, adj.2

50%117.9176.6Net sales (US$m)

GrowthQ3 2006Q3 2007

Financial Performance Exceeded Expectations

Third Quarter 2007At a Glance

1 US$172 million using January 31, 2007 foreign currency exchange rates 2 excluding acquisition, integration and relocation related charges as well as amortization of acquired IP and

equity-based compensation (SFAS 123R) 3 excluding acquisition, integration and relocation related charges as well as amortization of acquired IP and

equity-based compensation (SFAS 123R) and including a tax benefit of US$0.02 in EPS in Q3 2007

1

Financials


Fourth Quarter and Fiscal Year 2007 Guidance

0.13 – 0.14EPS (US$), adj2

Guidance Q4 20071

QIAGEN Significantly Increases EPS (adj.) Guidance by US$ 0.03

1 based on January 31, 2007 foreign currency exchange rates2 excluding acquisition, integration and relocation related charges as well as amortization of acquired IP and

equity-based compensation (SFAS 123R) 3 excluding acquisition, integration and relocation related charges as well as amortization of acquired IP and

equity-based compensation (SFAS 123R) as well as including a tax benefit of US$0.02in Q3 2007

0.55 – 0.59EPS (US$), adj.2, old0.61 – 0.62EPS (US$), adj.3, new

614 - 635Revenues (US$m)

Guidance FY 20071

Financials


Leading, focused: sample and assay technologiesStrong financial performance Strong growth projected: organic growth rate: ~15%

Proven innovation leadership in industrySuccessful acquisition track record

Core competency drives growth opportunitiesMDxPharma<->MDxApplied Testing

Leading catalytic acquisitions to expand:Sample and assay technology leadershipRegional footprint

Key Investment ConsiderationsSummary

QIAGEN – Sample and Assay Technologies...Global In Vitro Diagnostics Market By Segment (2006E)...

Documents

Transcript of QIAGEN – Sample and Assay Technologies...Global In Vitro Diagnostics Market By Segment (2006E)...